Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor.

Pediatric pulmonology - 1 Jul 2023

Baroud Evelyne, Chaudhary Nivedita, Georgiopoulos Anna M

Abstract excerpt

INTRODUCTION: Reports of neuropsychiatric symptoms proximal to cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their prevalence and management remain poorly characterized. METHODS: Retrospective chart review was used to categorize symptom trajectories of all adults at a single CF Center who initiated elexacaftor/tezacaftor/ivacaftor (ETI) before March 2022 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Quality of Life

Source

Identifiers

PMID: 37036050
DOI: 10.1002/ppul.26412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor.PMID 37036050Read ↗

Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor and Neuropsychiatric Symptoms: Nonclinical and Clinical StudiesSemantic proximity Read ↗

Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers.Semantic proximity Read ↗

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational StudySemantic proximity Read ↗

A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis.Semantic proximity Read ↗

DEPRESSION AND ANXIETY SYMPTOMS FOLLOWING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN ADULTS WITH CYSTIC FIBROSISSemantic proximity Read ↗

Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy.Semantic proximity Read ↗

Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Trikafta Experiences at a Quaternary CF Care CenterSemantic proximity Read ↗

Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

A retrospective analysis of clinical parameters, safety and tolerability of Elexacaftor/Tezacaftor/Ivacaftor in a cohort of patients aged 6-17 years with cystic fibrosisSemantic proximity Read ↗

Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.